Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Just the Facts, Ma'am: A Compendium of Liberal Fiction -- Ignore unavailable to you. Want to Upgrade?

To: Solon who wrote (40143)	9/13/2005 9:26:58 AM
From: Peter Dierks	Read Replies (1) \| Respond to of 90947

"It is probably reasonable to assume that most countries let their home grown drug companies extract a portion of their R&D costs from local consumers. It is truthful to say that most are barred from collecting them from other first world countries with the exception of America." ALL pharmaceutical initiatives require testing, etc. ... I think if the big Drug Dealers were being hard done by they would be quite poor. If all countries paid fairly for drug innovated in other countries drug companies would be a better investment, and the drug costs in the US would be much lower. If just a few countries like ones in the EU would pay fairly for innovation US drug costs would be much lower. (And drug costs in the country of innovation for each drug.) If drug costs were lower, and if we could rein in the jackpot justice of malpractice, US healthcare costs would be much lower. With a decline in costs (or at least a drastic decline in the rate of growth of medical costs) healthcare insurance would not be viewed as a luxury by many Americans who currently choose non-healthcare discretionary spending over paying for health insurance. "I have owned a Canadian Company for several years. INFLAZYME went through all the Necessaries and came up short." I came out better on IDBE.